Introduction
============

In the post-genomic era, examination of protein properties and functions of specific genes in transient and stable systems requires specific, nucleotide-level modification of large numbers of vector constructs carrying target genes. Therefore, a simple, flexible, low-cost and high-fidelity method for sequence modification is highly desirable for these processes. Sequence modification requires three types of manipulation: insertion, substitution and deletion. In conventional strategies, these sequence modifications are achieved in a cut-and-paste manner based on restriction endonucleases and modification enzymes such as ligases, phosphatases, kinases and others. This is tedious, time consuming and therefore expensive. In addition, finding suitable restriction site(s) in a specific vector and/or a target sequence can be problematic. These obstacles can be partially overcome by in vitro site-specific recombinational cloning ([@pct009-B9]) and by In-Fusion™ assembly ([@pct009-B21]), because of their fast reaction speeds and restriction enzyme-free nature. Although these technologies are commercially available as Invitrogen TOPO Gateway system and Clontech In-Fusion® kits, the high cost of the kits restricts their utility for routine vector construction in most molecular biology labs. Alternatively, numerous PCR-based cloning strategies and site-directed mutagenesis methods have been developed for their technical simplicity, low cost and high efficiency ([@pct009-B13], [@pct009-B11], [@pct009-B16], [@pct009-B7], [@pct009-B12], [@pct009-B3]), but most of these methods preferentially allow insertional sequence modification.

In 1989, Ho et al. reported development of the overlap extension site-directed mutagenesis technique, which enabled all three sequence modifications ([@pct009-B10]) and was adopted in the Stratagene QuikChange™ Site-Directed Mutagenesis Kit. This method requires supercoiled double-stranded DNA plasmid as template, two synthetic complementary oligonucleotides containing the desired point mutations as primers and the methylation-specific endonuclease *Dpn*I to remove the parental DNA template. [@pct009-B11] first reported the use of double-stranded PCR products as PCR primers. A similar concept, using 'megaprimers', was developed and modified in a number of PCR-based mutagenesis protocols to introduce a mutation into a gene of interest ([@pct009-B8], [@pct009-B18], [@pct009-B7], [@pct009-B12], [@pct009-B19]). However, these protocols incorporate the modification, particularly insertions or substitutions, into synthetic primers, which limits the capacity of PCR-based modification of longer sequences. To by-pass the primer length limitation, here we introduce a special design for chimeric primers and incorporate use of PCR products as megaprimers into the site-directed mutagenesis protocol, establishing a set of simple, effective and high capacity PCR-based molecular engineering strategies. The megaprimers generated from regular PCR with high-fidelity DNA polymerase are complementary, blunt-ended and suitable for overlap extension site-directed mutagenesis. Therefore, the capacity for sequence modification is no longer limited by primer synthesis. These strategies make use of a 'Ω-shaped' secondary structure(s) during PCR and we named this strategy 'Ω-PCR' based on this secondary structure formed in the reaction. The Ω-PCR technique enables precise long sequence modifications including substitution, deletion and insertion. In this report, we demonstrate the feasibility and application of Ω-PCR in the generation of constructs for expressing fusion proteins, swapping fluorescent tags and removing subcellular sorting signals. This technology has broad implications for protein engineering, in vitro gene splicing and gene function analysis.

Results
=======

The Ω-PCR strategy comprises three modes (insertion/substitution/deletion); their principles are illustrated in [Figs. 1--3](#pct009-F1 pct009-F2 pct009-F3){ref-type="fig"}. To demonstrate the feasibility and robustness of Ω-PCR, a *pBI221*-based construct (*pBI-GFP:OsRac3*) for transient expression of a fusion of green fluorescent protein (GFP) with OsRac3 (GFP:OsRac3), a plasma membrane-localized small GTPase from rice (*Oryza sativa* L.) ([@pct009-B6]), served as the original construct for subcellular localization assays and was modified by substitution, deletion and insertion modes of Ω-PCR, in succession. Fig. 1Substitution Ω-PCR. (A) Principle of substitution mode Ω-PCR. The original construct (*pBI-GFP:OsRac3*) is the plasmid to be manipulated. The *GFP* fragment (green) is a DNA fragment intended to be replaced by a photoactivatable fluorescent protein gene *Den* (brown) at a specific site in the original construct. The chimeric forward primer (Vec-Den-F) consists of two parts: the 5′ portion (red) is identical to the vector backbone sequence at the 5′ junction of modification site 1 (ms1) and the 3′ portion (brown) is identical to the 5′ region of *Den*; the chimeric reverse primer (Den-Rac3-R) also consists of two parts: the 5′ portion (blue) corresponds to the *OsRac3* sequence at the 3′ junction of the modification site 2 (ms2) and the 3′ portion (brown) corresponds to the 3′ region of the *Den* fragment. The denatured strands of the first PCR product containing *Den* (brown) serve as de novo 'megaprimers' for substitution Ω-PCR in the following reaction. To simplify the figure, only the forward megaprimer and one strand of the plasmid template are shown in the preceding steps and figures. When the 'megaprimer' anneals to the template, the sequences of *GFP* (green) and *Den* (brown) form individual Ω-shaped structures. (B) The *GFP* sequence in the *pBI-GFP:OsRac3* construct was replaced by *Den* through substitution Ω-PCR, resulting in a new construct, *pBI-Den:OsRac3*. Lane 1, the first run PCR product *Den*; lane 2, the second run PCR product *pBI-Den:OsRac3*; lane 3, the starting plasmid *pBI-GFP:OsRac3* digested with *Bam*HI; \* indicates target product bands; Marker, Trans15K DNA ladder (TransGen Biotech). Fig. 2Deletion Ω-PCR. (A) Principle of deletion mode Ω-PCR. *OsRac3* is a sequence to be deleted from the starting construct *pBI-Den:OsRac3*. The chimeric forward primer Den-Vec-F consists of two parts: the 5′ portion (brown) is identical to the *Den* sequence at the 5′ region of the modification site 2 (ms2) and the 3′ portion (cyan) is identical to the vector sequence at the 3′ region of the modification site 3 (ms3). The chimeric reverse primer Den-Vec-R is complementary to the chimeric forward primer Den-Vec-F. The deletion mode is conducted in only one PCR. When the chimeric primer anneals to the template, the deleted fragment of *OsRac3* forms a Ω-shaped structure, and ms2 and ms3 link together forming ms2/3. (B) The *OsRac3* sequence in *pBI-Den:OsRac3* was deleted via deletion mode Ω-PCR, resulting in the *pBI-Den* construct. The starting plasmid *pBI-Den:OsRac3* was digested by *Bam*HI; \* indicates target product bands; Marker, Trans15K DNA ladder (TransGen Biotech). Fig. 3Insertion Ω-PCR. (A) Principle of insertion mode Ω-PCR. Coding sequence of a Golgi sorting protein Rer1B is to be inserted into the starting construct *pBI-Den.* The 5′ portion (brown) of the forward chimeric primer Rer1B-F for insertion mode Ω-PCR is identical to the 5′-flanking sequence of the modification site 2/3 (ms2/3) and the 3′ portion of the forward primer (purple) is identical to the 5′ end of insert *Rer1B*. The 5′ portion (cyan) of the reverse chimeric primer Rer1B-R corresponds to the 3′-flanking sequence of the ms2/3 in the vector and the 3′ portion (purple) of the reverse primer corresponds to the 3′ end of the insert *Rer1B*. A *Rer1B*-containing fragment is PCR-amplified using Rer1B-F and Rer1B-R and serves as de novo 'megaprimers' for insertion in the following Ω-PCR. (B) *Rer1B* was cloned into a vector containing the *Den* gene through insertion Ω-PCR, resulting in a fused Golgi marker *pBI-Den:Rer1B.* Lane 1, the PCR product of *Rer1B*; lane 2, the second PCR product containing *pBI-Den:Rer1B*; lane 3, the starting plasmid *pBI-Den*, which was digested with *Bam*HI; \* indicates target product bands; Marker, Trans15K DNA ladder (TransGen Biotech).

Substitution Ω-PCR
------------------

The principle of substitution Ω-PCR is illustrated in [Fig. 1](#pct009-F1){ref-type="fig"}A. We designed a pair of chimeric primers for replacement of *GFP* with the gene encoding the photoactivatable fluorescent protein Dendra2 (Den) ([@pct009-B15]). The 5′ sequences of the forward chimeric primer (Vec-Den-F) and the reverse chimeric primer (Vec-Den-R) were identical to the flanking sequences of the starting plasmid, while the 3′ parts of these primers were identical to the 5′ end and 3′ end of the *Den* coding sequence, respectively ([Fig. 1](#pct009-F1){ref-type="fig"}A; [Supplementary Table S1](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)). In the first PCR, the target *Den* fragment was amplified from a *Den*-containing template with the chimeric primers. Two tails identical to the flanking sequence were integrated in the resultant PCR product ([Fig. 1](#pct009-F1){ref-type="fig"}A, B, first lane). In the second PCR, the destination vector *pBI-GFP:OsRac3* served as the template and the denatured strands of the *Den*-containing PCR product served as megaprimers annealing to the complementary sequence of the destination vector through the two flanking tails. The Ω-shaped structure in the megaprimer was then extended by high-fidelity DNA polymerase along the vector during thermocycling. Thereby, the *GFP* fragment was replaced by the target *Den* fragment in the de novo circular plasmid with two staggered nicks at the end ([Fig. 1](#pct009-F1){ref-type="fig"}A, B, second lane). The template plasmids isolated from *Escherichia coli* are usually methylated and can be digested by the restriction endonuclease *Dpn*I, whereas in vitro synthesized DNA (PCR products) is resistant to this enzyme ([@pct009-B20]). After treatment with *Dpn*I to remove the original template plasmids, the PCR product was transferred into *E. coli*. The *pBI-Den:OsRac3* transformants were screened with a forward primer (F1) on the vector and a reverse primer (R1-2) within the target *Den* ([Fig. 1](#pct009-F1){ref-type="fig"}A), and the rate of positive colonies was about 95% ([Table 1](#pct009-T1){ref-type="table"}; [Supplementary Fig. S1A](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)). Table 1Capacity and efficiency of the Ω-PCR strategyMode of Ω-PCRFinal plasmid nameFinal plasmid size (kb)Starting plasmid size (kb)Sub/Del/Ins size (kb)Positive rateSub*pBI-Den:OsRac3*7.57.50.71794.7%Del*pBI-Den*6.97.50.645100%Ins*pBI-Den:Rer1B*7.56.90.58593.0%Ins*pBI-Den:GEN-L*8.86.91.8994.4%Sub*pENTR-cPita*5.43.32.78793.7%Ins*pYLTAC747-Den*16.515.80.71778.5%[^1][^2]

Deletion Ω-PCR
--------------

The principle of deletion Ω-PCR is illustrated in [Fig. 2](#pct009-F2){ref-type="fig"}A. The *pBI-Den:OsRac3* vector resulting from the substitution Ω-PCR was used as template to test the deletion mode of Ω-PCR. In this case, only complementary chimeric primers were applied. When the two portions of the chimeric primers annealed to their complementary sites on the target construct, the *OsRac3* coding region in the template formed a Ω-shaped structure, and the *OsRac3*-containing loop region of the Ω-shaped structure was removed in the de novo PCR product ([Fig. 2](#pct009-F2){ref-type="fig"}A, B). After treatment with *Dpn*I, the PCR product was transformed into *E. coli* competent cells. The resultant *pBI-Den* transformants were screened using a pair of primers, F1/R2, flanking the deletion site ([Fig. 2](#pct009-F2){ref-type="fig"}A; [Supplementary Fig. S1B](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)), and the positive rate was about 100% ([Table 1](#pct009-T1){ref-type="table"}).

Insertion Ω-PCR
---------------

The principle of insertion Ω-PCR is illustrated in [Fig. 3](#pct009-F3){ref-type="fig"}A. The *pBI-Den* vector resulting from deletion Ω-PCR was further modified using the insertion mode. Similar to substitution, the target *Rer1B* being inserted was amplified from a *Rer1B*-containing template with chimeric primers in the first PCR ([Fig. 3](#pct009-F3){ref-type="fig"}B). In the second PCR, the denatured strands of the *Rer1B*-containing PCR products served as megaprimers annealing to the flanking sequences of the insertion site on the plasmid to form a Ω-shaped structure. Thereby, *Rer1B* was integrated into the target constructs. After treatment with *Dpn*I, the PCR product was transformed into *E. coli* competent cells. The *pBI-Den:Rer1B* transformants were screened by a pair of primers, F3/R2 ([Fig. 3](#pct009-F3){ref-type="fig"}A; [Supplementary Fig. S1C](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)), and the positive rate was about 93% ([Table 1](#pct009-T1){ref-type="table"}).

One-tube Ω-PCR
--------------

To simplify the procedures for substitution and insertion modes, we applied exonuclease I to the Ω-PCR, so that these modes could be executed using a one-tube method. In the two-step protocol, the first PCR was performed with 28--30 cycles, and 2--3 µl of the first PCR product was supplied as megaprimers for the second reaction (20 µl). We found that the amount of the megaprimers used in the second reaction was equivalent to that generated by about 12--15 cycles of the first-round PCR ([Fig. 4](#pct009-F4){ref-type="fig"}A). Since exonuclease I digests only single-stranded DNA without affecting double-stranded DNA, after 12--15 cycles of amplification we added this enzyme to the PCR to remove the remaining chimeric primers, and added 5--10 ng of the plasmid to be modified for further amplification. In this way we obtained the expected constructs with substituted or inserted target fragments in one-tube reactions ([Fig. 4](#pct009-F4){ref-type="fig"}B). Fig. 4One-tube Ω-PCR strategy. (A) For the first phase of the one-tube Ω-PCR strategy, we determined that the amount of target sequence in 5 µl of product from a 15-cycle amplification was approximately equal to the amount in 0.5 µl of PCR product produced by 30 cycles of amplification. Therefore, the total amount of the target product in the 20 µl reaction from the 15-cycle amplification in the one-tube strategy was equal to approximately 2 µl of the fully amplified product added to the second PCR in the two-step strategy. (B) Use of one-tube Ω-PCR for insertion and substitution modifications in plasmid construction. Constructs *pBI-Den:OsRac3* (left) and *pBI-Den:Rer1B* (right) were generated by substitution or insertion mode Ω-PCR using the one-tube method; Marker, Trans15K DNA ladder (TransGen Biotech).

Capacity and efficiency of the Ω-PCR strategy
---------------------------------------------

To test the capacity and efficiency of the Ω-PCR strategy, we used different modes of Ω-PCR for sequence modification of two other gene fragments: *OsGEN-L* (1.89 kb) ([@pct009-B17]) and *Pi-ta* cDNA (2.787 kb) ([@pct009-B2]), and two vector backbones: *pENTR* (2.6 kb) (Invitrogen) and *pYLTAC747* (15.8 kb) ([@pct009-B14]). The results showed that Ω-PCR can handle large plasmids with sizes ranging from 5.4 to 16.5 kb ([Fig. 5](#pct009-F5){ref-type="fig"}, [Table 1](#pct009-T1){ref-type="table"}). Fig. 5Capacity of the Ω-PCR strategy. Plasmids of various sizes were manipulated by Ω-PCR. A nuclear marker *GEN-L* (1.89 kb) was inserted into *pBI-Den* plasmid (6.9 kb); *cPita*, a cDNA of resistance gene *Pi-ta* (2.787 kb) was substituted with *GFP* in the *pENTR-GFP* plasmid (3.3 kb); a photoactivatable fluorescent protein gene *Den* (0.717 kb) was inserted into the *pYLTAC747* plasmid (15.8 kb). \* indicates target product bands; Marker, Trans15K DNA ladder (TransGen Biotech).

Sequence and functional validation of constructs modified by Ω-PCR strategies
-----------------------------------------------------------------------------

We sequenced the junction regions in the three vector constructs modified in succession by the Ω-PCR strategies. A diagram and the sequences of the three junction regions in the original vector *pBI-GFP:OsRac3* are shown in [Fig. 6](#pct009-F6){ref-type="fig"}A and [B](#pct009-F6){ref-type="fig"}, and these regions were re-sequenced for verification after modification ([Fig. 6](#pct009-F6){ref-type="fig"}C--E). We found that all three resultant plasmids had been correctly modified. These plasmids were transiently expressed in rice protoplasts to confirm the subcellular localizations of the resultant proteins in vivo ([Fig. 7](#pct009-F7){ref-type="fig"}). Indeed, Den:OsRac3 (*pBI-Den:OsRac3*) was localized in the plasma membrane like the original GFP:OsRac3 (*pBI-GFP:OsRac3*). The Den (*pBI-Den*) fluorescent protein alone was distributed in the cytoplasm and Den:Rer1B (*pBI-Den:Rer1B*) was localized in the Golgi, as expected. All of the Den proteins in the different constructs were able to be photoactivated by a 405 nm laser and properly converted from green to red ([Fig. 7](#pct009-F7){ref-type="fig"}). Fig. 6Validation of the modified constructs by sequencing. (A) Schematic diagram of the original construct *pBI-GFP:OsRac3* used for manipulation. In substitution mode, *GFP* was replaced by *Den*, which encodes a photoconvertible fluorescent protein Den, resulting in *pBI-Den:OsRac3*. *OsRac3* was then removed from *pBI-Den:OsRac3*, resulting in *pBI-Den*. *Rer1B* encoding a Golgi protein was inserted into the 3′ region of *Den* using insertion mode, resulting in *pBI-Den:Rer1B*. Junctions 1--3 represent the flanking regions of the modification sites (ms). (B) Original sequences of the three junction regions of *pBI-GFP:OsRac3* shown in (A). (C--E) Sequence confirmation of the junction regions in the modified constructs produced by different Ω-PCR modes. Primers F1--F4 indicated in (A) were used for sequencing analysis. The arrowheads indicate the modification sites. Fig. 7Subcellular localization of fusion proteins expressed from the plasmids manipulated by Ω-PCR techniques. GFP:OsRac3 (*pBI-GFP:OsRac3*) was localized in the plasma membrane (upper left), as was Den:OsRac3 (*pBI-Den:OsRac3*, upper right); Den (*pBI-Den*) was localized in the cytoplasm (bottom left); Den:Rer1B (*pBI-Den:Rer1B*) was localized in the Golgi (bottom right). The Den signal in the oval or circular regions of the right panels was converted from green to red by photoactivation with a 405 nm laser. The signals were collected separately and merged using two pseudocolors. Bars = 5 µm.

Discussion
==========

Although a number of PCR-based cloning and mutagenesis approaches have been reported, most of them are useful for only one type of sequence modification; those that can be used for insertion or substitution can handle only very short sequences. The Ω-PCR methods described herein can be used to manipulate large sequences, and therefore enable all types of sequence modification. The key principle of our Ω-PCR sequence modification strategies is the formation of the characteristic secondary structure between the megaprimers (target PCR products) and templates (plasmids) during the PCR. The formation of this secondary structure is attributable to the specific design of the chimeric primers. Several overlapping extension cloning protocols which allow only insertion sequence modification have been reported ([@pct009-B4], [@pct009-B3], [@pct009-B1]), However, our Ω-PCR methods enable all three types of modification in one-tube reactions.

In the two-step reactions, the chimeric primers carried into the second PCR are highly diluted, and thus do not affect the Ω-PCR. However, for the one-tube Ω-PCR strategy without exonuclease I treatment, the first PCR product was preferentially amplified in the second PCR phase, leading to failure of amplification of the target plasmid (data not shown). However, reducing the concentration of the chimeric primers often resulted in low amplification efficiency. One of the novel features of the one-tube Ω-PCR strategy is the utilization of exonuclease I to remove the extra chimeric primers in the second round of PCR to avoid these problems. Therefore, no gel purification step of the target fragment is required in either of the strategies. In addition, Ω-PCRs do not require post-PCR procedures such as restriction enzyme digestions and ligation.

The Ω-PCR technique can be used to insert, swap or remove any fragment at any position of a circular plasmid for functional analysis. The Ω-PCR insertion mode enables subcloning of a target gene directly into a destination plasmid vector by PCR alone. This strategy overcomes the limitation of conventional restriction--ligation-based cloning methods. The substitution mode of Ω-PCR can be used to exchange fluorescent protein genes, fusion tags or subcellular sorting signals, and the deletion mode can be used to generate a series of truncated gene fragments for deletion assays. It is also a very good choice for in vitro splicing to remove introns from genomic DNA (gDNA) without the need for reverse transcription to clone full-length cDNA for long genes with few introns. Using deletion Ω-PCR, we have successfully obtained a full length *Pi-ta* cDNA (2,787 bp) from gDNA (4,250 bp) (containing one 1.5 kb intron, data not shown). The only limitation for Ω-PCR is the capacity of the DNA polymerase for amplification of longer DNA fragments (target sequences and plasmid vectors). We highly recommend using a DNA polymerase of high performance and high fidelity, such as PrimeSTAR, Pfx, Pfu, KOD or Phusion, to increase the efficiency and fidelity of the Ω-PCR. Using the PrimeSTAR *Taq* DNA polymerase, 1.89 and 2.787 kb fragments were successfully inserted or substituted into target plasmids by Ω-PCR ([Fig. 5](#pct009-F5){ref-type="fig"}, [Table 1](#pct009-T1){ref-type="table"}). The *Den* fragment was inserted into a transformation-competent artificial chromosome (TAC) vector *pYLTAC747* with a final size of 16.5 kb ([Fig. 5](#pct009-F5){ref-type="fig"}, [Table 1](#pct009-T1){ref-type="table"}), demonstrating that the capacity of Ω-PCR is sufficient to handle most common binary vectors (9--14 kb) for plant transformation. The efficiency of Ω-PCR is around 10^5^--10^7^c.f.u. µg^−1^ and the positive rate of transformants ranges from 75% to 100% ([Table 1](#pct009-T1){ref-type="table"}). Thus, the Ω-PCR technique is speedy, effective and inexpensive, and will benefit molecular biologists by accelerating the efficiency of functional studies of target genes.

Materials and Methods
=====================

Design of Ω-PCR primers
-----------------------

*Primers for substitution of GFP with Den.* Forward primer Vec-Den-F for substitution mode Ω-PCR consisted of a 21 base 5′ portion identical to the 5′-flanking sequence of the modification site 1 (ms1) on the vector, and a 21 base 3′ portion identical to the 5′ end of the insert *Den*. The 5′ portion (20 bases) of reverse primer Den-Rac3-R corresponded to the 5′ end of *OsRac3*, and the 3′ portion (21 bases) of Den-Rac3-R corresponded to the 3′ end of the insert *Den* ([Supplementary Table S1](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)).

*Primers for deletion of OsRac3.* The primers for deletion mode Ω-PCR also consisted of two parts demarcating the ms2 and ms3. The 5′ portion of the forward primer Den-Vec-F consisted of 18 bases and was identical to the 5′-flanking sequence of the ms2, and the 3′ portion (25 bases) of Den-Vec-F was identical to the 3′-flanking sequence of the ms3. The reverse primer Den-Vec-R was reversed and complementary to the forward primer Den-Vec-F ([Supplementary Table S1](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)).

*Primers for insertion of Rer1B.* The 5′ portion (22 bases) of forward primer Rer1B-F for insertion mode Ω-PCR was identical to the 5′-flanking sequence of the ms2/3 in the plasmid *pBI-Den*, and the 3′ portion of the forward primer consisted of 21 bases and was identical to the 5′ end of insert *Rer1B*. The 5′ portion of the reverse primer Rer1B-R consisted of 21 bases and corresponded to the 3′-flanking sequence of the ms2/3 in the vector, and the 3′ portion of the reverse primer consisted of 21 bases and corresponded to the 3′ end of the insert *Rer1B* ([Supplementary Table S1](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)).

Two-step Ω-PCR
--------------

For Ω-PCR insertion and substitution modes, Ω-PCR could be conducted in a two-step reaction. In the first reaction, the PCR mixture contained 4.0 µl of 5× PS buffer, 0.2 mM dNTPs, 0.5 µM each of the chimeric primers, and 1--5 ng of template DNA (such as plasmid DNA or gDNA) containing the target insertion sequence or substitution fragment, 0.3 U of PrimeSTAR *Taq* DNA polymerase (TAKARA) and deionized water to a final volume of 20 µl. A *Taq* DNA polymerase that produces blunt-end products must be used for this technique. The PCR mixture was subjected to 28--30 cycles of 96°C for 20 s, 60°C for 30 s, 72°C for 1--5 min (according to the size of the amplified fragment, approximately 45--60 s kb^--1^). In the second-step PCRs, 2--3 µl of the PCR product resulting from the first reaction served as the megaprimer, and 5--10 ng of the plasmid being modified served as template; PCR buffer, dNTPs and *Taq* DNA polymerase were present in the same amounts as in the first reaction. The PCRs were conducted with five cycles of 96°C for 30 s, 55°C for 1 min, 68°C for 5--10 min (according to the final size of the plasmid, approximately 1 min kb^--1^), followed by 10--15 cycles of 96°C for 1 min, 68°C for 5--10 min. The resultant final PCR products were treated at 37°C for 30 min with 5--10 U of *Dpn*I to digest specifically the original template plasmids.

One-tube Ω-PCR
--------------

Since current PCR machines possess very powerful programming capability, Ω-PCR steps can be performed in the same tube with one program using the link or insertion function of PCR machines such as ABI PE9700 or TAKARA TP650. In the one-tube Ω-PCR, the PCR mixture contained 4.0 µl of 5× PS buffer, 0.25 mM dNTPs, 0.5 µM each of the chimeric primers, 1--5 ng of template DNA containing the target insertion or substitution fragment, 0.5 U of PrimeSTAR *Taq* DNA polymerase (TAKARA) and deionized water to a final volume of 20 µl. After amplification of the insertion or substitution fragment by 12--16 cycles of 96°C for 20 s, 60°C for 30 s, 72°C for 1--5 min, 5--10 U of exonuclease I (NEB) was applied to digest the remaining chimeric primers at 37°C for about 10 min. Then 5--10 ng of the plasmid to be modified was added as the second template, followed by five cycles of 96°C for 30 s, 55°C for 1 min, 68°C for 8 min, and 15 cycles of 96°C for 1 min, 68°C for 8 min. The final PCR products were treated at 37°C for 30 min with 5--10 U of *Dpn*I to destroy the original template plasmids.

Among the three Ω-PCR modes, the deletion mode did not involve megaprimers and was accomplished in one-tube reactions. PCR mixture contents and conditions were as follows: 4.0 µl of 5× PS buffer, 0.20 mM dNTP, 0.5 µM of each chimeric primer, 1--5 ng of the plasmid being modified as template, 0.5 U of PrimeSTAR *Taq* DNA polymerase (TAKARA) and deionized water to a final volume of 20 µl. Five cycles of 96°C for 30 s, 55°C for 1 min, 68°C for 5--10 min (according to the final size of the plasmid, approximately 1 in kb^--1^), and 15 cycles of 96°C for 1 min, 68°C for 5--10 min were carried out. The final PCR products were treated at 37°C for 30 min with 5--10 U of *Dpn*I.

Sequence validation of modified constructs
------------------------------------------

The *Dpn*I-treated final PCR products were dialyzed against 0.3× TE buffer and 1--2 µl of the products were transferred into *E. coli* (DH5α or DH10B) competent cells by electroporation. Resultant colonies were screened by colony PCR with specific primer pairs ([Supplementary Table S1](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)). The modified plasmids were extracted from positive clones with a plasmid purification kit (Qiagen) and sequenced with specific primers ([Supplementary Table S1](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1)).

Transient assays of modified vectors
------------------------------------

Preparation of rice protoplast cells and transfection with plasmids were carried out as described previously ([@pct009-B5]). Confocal microscopy was performed with an LSM710 (Carl Zeiss). A 488 nm laser was used to excite non-photoconverted Den (detection at 500--550 nm, green); Den was photoactivated by a 405 nm laser and excited by 543 nm lasers (detection at 550--670 nm, red). The two signals from Den were collected separately in sequential mode and merged with the use of two pseudocolors (green and red).

Supplementary data
==================

[Supplementary data](http://pcp.oxfordjournals.org/lookup/suppl/doi:10.1093/pcp/pct009/-/DC1) are available at PCP online.
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Den

:   Dendra2 fluorescent protein

gDNA

:   genomic DNA

GFP

:   green fluorescent protein

Ω-PCR

:   omega-PCR

TAC

:   transformation-competent artificial chromosome.

[^1]: Competent cell efficiency tested by *pUC19* was 9.3 × 10^9^c.f.u. µg^−1^.

[^2]: Sub, substitution; Del, deletion; Ins, insertion. Positive rate was calculated based on the colony PCR results of 120--150 random clones.
